Strategic Advisory Oblique Therapeutics AB recently added a Scientific Advisor, indicating an openness to expert guidance and potential collaboration opportunities with industry veterans to accelerate research and negotiations for co-development or sponsored programs.

Pain focused The company’s internal pipeline centers on pain and TRPV1 targeting, presenting a clear entry point for partnering with CROs, contract research services, and pharma companies seeking analgesia innovations or peptide/antibody therapies for chronic pain indications.

Antibody Platform Leveraging the proprietary Abiprot antibody platform to access intracellular or hard-to-reach epitopes opens doors for collaboration with biotech players needing next-generation antibody technologies, potentially enabling licensing deals or joint ventures.

External Collaborations Past and ongoing partnerships with AAX Biotech and Targovax suggest a proven model for external collaborations; market outreach can target mid-size pharma and biotech seeking antibody-based modalities for pain and intracellular targets.

Funding & Growth With a current revenue under one million and about two to ten employees, there may be appetite for early-stage partnerships, grant-supported programs, or strategic investments to scale further development and move candidates toward clinical milestones.